Jump to content
CJC-1295 Medicine

An unrolled scroll of what the medical literature actually says about CJC-1295 — the GHRH analog, the DAC variant, the discontinued clinical program.

WHERE EACH CLAIM COMES FROM

Which sources support the facts about CJC-1295?

The main CJC-1295 human paper measured blood hormones and short-term harm. Other sources cover animals, government action, sports rules, and public trials. Each note points to a source.

Which paper answers each kind of question?

I begin with the 2006 stage 1 paper, an early human test. It tells how fast CJC-1295 left blood and how hormones changed after each shot. A 2005 paper tested rats and rat growth-gland cells. The drug bound albumin, a common blood protein, and made the cells release growth hormone.

Papers from 2010 and 2019, plus a 2021 review, ask whether labs can find the drug in a sample, while the 2024 U.S. pharmacy paper covers whether pharmacies could use its powder to make custom medicine for one patient. Advisers didn't support that use. The sports list bars athletes from using CJC-1295. These sources don't prove the drug will help you or stay safe.

Each note number points to a source. A paper can answer a fact question, but your doctor must still weigh your health.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  3. Jetté L, Léger R, Thibaudeau K, et al. Identification of CJC-1295 as a long-lasting GRF analog: rat anterior pituitary cell pharmacology and in vivo plasma persistence (preclinical findings). Endocrinology. 2005;146(7):3052-3058. ↗
  4. Jetté L, Léger R, et al. DPP-IV resistance and extended in vitro plasma stability of tetrasubstituted GHRH(1-29) (preclinical PK data, same source as ref 2/3). Endocrinology. 2005;146(7):3052-3058. ↗
  5. Zhou F, Zhang H, Cong Z, Zhao L-H, Zhou Q, Mao C, Cheng X, Xu HE, et al. Structural basis for activation of the growth hormone-releasing hormone receptor. Nat Commun. 2020;11(1):5205. ↗
  6. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat. J Clin Endocrinol Metab. 2010;95(9):4291-4304. ↗
  7. aidsmap (NAM Publications). Lipodystrophy study halted after patient death. News report on ConjuChem Phase II program. 2006. ↗
  8. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
  9. Timms M, Hall N, Levina V, Vine J, Steel R. A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug Test Anal. 2019;11(7):1085-1093. ↗
  10. Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009;296(5):E1085-E1092. ↗
  11. Bridon DP, ConjuChem Inc. Drug Affinity Complex (DAC) technology overview. 2005. ↗
  12. Modified GRF (1-29) pharmacology overview. Review article citing original GHRH analog pharmacology literature. 2024. ↗
  13. Jetté L, Léger R, et al. Albumin-bound CJC-1295 immunoreactivity in rat plasma — appears within 15 minutes, persists beyond 72 hours (preclinical PK data, same source as ref 2/3). Endocrinology. 2005;146(7):3052-3058. ↗
  14. World Anti-Doping Agency. The 2025 Prohibited List. WADA Code Prohibited List, annual publication. 2025. ↗
  15. ConjuChem Biotechnologies (sponsor). A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. ClinicalTrials.gov identifier NCT00267527. 2007. ↗
  16. Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;13(11-12):1871-1887. ↗
  17. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) Meeting; Bulk Drug Substances Nominated for Inclusion on the 503A Bulk Drug Substances List. December 2024 briefing documents. ↗
  18. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (NIH). Tesamorelin. NCBI Bookshelf. 2020. ↗
  19. Theratechnologies / U.S. Food and Drug Administration. EGRIFTA (tesamorelin for injection) Full Prescribing Information. FDA Drug Label. 2019. ↗